Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome

J Dtsch Dermatol Ges. 2020 Mar;18(3):193-197. doi: 10.1111/ddg.14044. Epub 2020 Feb 20.

Abstract

Radiotherapy, particularly total skin electron beam therapy (TSEB), is one of the main pillars in the strategy for treatment of cutaneous T-cell lymphoma (CTCL). Low-dose TSEB has gained considerable attention since it has a minimal toxicity profile. Low-dose TSEB has been shown to yield an overall response rate up to 95 %, although the response duration is usually short. Few studies have been published on treatment outcomes after combined treatment of CTCL with TSEB and systemic therapy. Remission rates of patients who received immune checkpoint inhibitors alone ranged from 15-38 % with a two-year progression-free survival of 69 %. Given that TSEB results in rapid reduction of the disease burden in almost all patients, we hypothesized that TSEB followed by immune checkpoint inhibitors might be a reasonable treatment with a sustained effect for treatment-experienced patients with mycosis fungoides and Sezary syndrome.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Male
  • Mycosis Fungoides / radiotherapy
  • Mycosis Fungoides / therapy*
  • Radiotherapy Dosage
  • Sezary Syndrome / therapy*
  • Skin Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors